Clinical Trial Detail

NCT ID NCT03937219
Title Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Exelixis
Indications

clear cell renal cell carcinoma

Therapies

Cabozantinib + Nivolumab

Ipilimumab + Nivolumab

Cabozantinib + Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.